Biolitec Pharma files annual return

Biolitec Pharma has given the details of its directors and shareholders in its annual return. The company’s directores are Dr Wolfgang Neuberger, Dr Winrich Rausching while its shareholders have 1,000 ordinary shares as of August 2008. Biolitec Pharma produced palliative treatment Foscan for head and neck cancer (temoporfin).